Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name SF3B1 K700E
Gene Variant Detail

SF3B1 K700E (loss of function)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
SF3B1 K700E myelodysplastic syndrome not applicable N/A Guideline Prognostic SF3B1 K700E is associated with a more favorable prognosis in patients with myelodysplastic syndrome (NCCN.org). detail...
SF3B1 K700E pancreatic cancer sensitive H3B-8800 Preclinical - Cell culture Actionable In a preclinical study, H3B-8800 inhibited aberrant splicing and preferentially induced apoptosis in pancreatic cancer cells harboring SF3B1 K700E compared to SF3B1 wild-type cell lines in culture (PMID: 29457796). 29457796
SF3B1 K700E chronic lymphocytic leukemia predicted - sensitive Sudemycin D1 Preclinical - Patient cell culture Actionable In a preclinical study, Sudemycin D1 treatment resulted in increased cytotoxicity (p<0.05) in chronic lymphocytic leukemia cells derived from patients harboring mutations in SF3B1 (n=14) or other RNA splicing/processing genes (n=8) compared to cells derived from patients without mutations (n=10) in culture, including 2 cell lines harboring SF3B1 K700E (PMID: 26068951). 26068951
SF3B1 K700E acute myeloid leukemia predicted - sensitive E7820 Preclinical - Cell culture Actionable In a preclinical study, an acute myeloid leukemia cell line engineered to express SF3B1 K700E from the endogenous locus demonstrated increased sensitivity to E7820 induced growth inhibition compared to parental cells in culture (PMID: 30799057). 30799057
SF3B1 K700E pancreatic cancer sensitive Spliceostatin A Preclinical Actionable In a preclinical study, Spliceostatin A inhibited survival of pancreatic cancer cells harboring SF3B1 K700E in culture (PMID: 25424858). 25424858
SF3B1 K700E chronic myeloid leukemia sensitive GSK3203591 + MS023 Preclinical - Cell culture Actionable In a preclinical study, MS023 and GSK3203591 synergistically inhibited survival of a chronic myeloid leukemia cell line with knockin SF3B1 K700E in culture (PMID: 31408619). 31408619
SF3B1 K700E acute myeloid leukemia sensitive H3B-8800 Preclinical - Pdx Actionable In a preclinical study, H3B-8800 inhibited aberrant splicing and tumor growth in a cell line xenograft and a patient-derived xenograft (PDX) model of acute myeloid leukemia harboring SF3B1 K700E (PMID: 29457796). 29457796
SF3B1 K700E acute myeloid leukemia sensitive H3B-8800 Preclinical - Cell culture Actionable In a preclinical study, H3B-8800 preferentially inhibited growth of mouse acute myeloid leukemia cells harboring SF3B1 K700E compared to SF3B1 wild-type cells in culture (Blood 2016 128:966). detail...
SF3B1 K700E B-cell acute lymphoblastic leukemia sensitive Indisulam Preclinical - Cell culture Actionable In a preclinical study, a B-cell acute lymphoblastic leukemia cell line engineered to express SF3B1 K700E from the endogenous locus demonstrated increased sensitivity to Indisulam (E7070) induced growth inhibition compared to parental cells in culture (PMID: 30799057). 30799057
SF3B1 K700E hematologic cancer sensitive E7107 Preclinical - Cell culture Actionable In a preclinical study, mouse cells expressing SF3B1 K700E demonstrated sensitivity to E7107 in culture, resulting in decreased viability of cells (PMID: 27622333). 27622333
SF3B1 K700E chronic myeloid leukemia sensitive H3B-8800 Preclinical - Cell line xenograft Actionable In a preclinical study, H3B-8800 preferentially induced cell death in a chronic myeloid leukemia cell line expressing SF3B1 K700E in culture, inhibited aberrant splicing and tumor growth in a cell line xenograft model (PMID: 29457796). 29457796
SF3B1 K700E chronic myeloid leukemia sensitive H3B-8800 Preclinical - Cell line xenograft Actionable In a preclinical study, H3B-8800 inhibited tumor growth in cell line xenograft models of chronic myeloid leukemia harboring SF3B1 K700E while had no effect in SF3B1 wild-type controls (Blood 2016 128:966). detail...
SF3B1 K700E acute myeloid leukemia sensitive Indisulam Preclinical - Cell culture Actionable In a preclinical study, an acute myeloid leukemia cell line engineered to express SF3B1 K700E from the endogenous locus demonstrated increased sensitivity to Indisulam (E7070) induced growth inhibition compared to parental cells in culture (PMID: 30799057). 30799057
SF3B1 K700E B-cell acute lymphoblastic leukemia sensitive E7820 Preclinical - Cell culture Actionable In a preclinical study, a B-cell acute lymphoblastic leukemia cell line engineered to express SF3B1 K700E from the endogenous locus demonstrated increased sensitivity to E7820 induced growth inhibition compared to parental cells in culture (PMID: 30799057). 30799057
Clinical Trial Phase Therapies Title Recruitment Status